Evidence map›Paper›PMID 20586956›Full record

SynthesisTropical medicine & international health : TM & IH2010

Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.

Matthew P Fox, Sydney Rosen

Registry-linked trialAbstract readSystematic Review
In one paragraph

Synthesis in Tropical medicine & international health : TM & IH, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01992887 (Retention and Engagement in Care of Patients Prior to ART Initiation in the Kagera Region of Tanzania), which is not on this map. Cited by 329 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
329citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01992887 completednot on this mapstarted 2012, after this paper: background citation

Retention and Engagement in Care of Patients Prior to ART Initiation in the Kagera Region of Tanzania

Typeobservational_patient_registrySponsorColumbia UniversityRan2012 to 2016Enrolled948ConditionsHIV (Human Immunodeficiency Virus), AIDS (Acquired Immunodeficiency Syndrome)
3 · Its place in the literature

Who cites it

329 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

269 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Matthew P FoxCenter for Global Health and Development, Boston University, Boston, MA 02118, USA. mfox@bu.edu
Sydney Rosen

Funding

Rates, Predictors and Mortality Impact of Losses from HIV Care in South AfricaK01AI083097 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FOX, MATTHEW ALEXANDER PEASE · 2009 to 2013
$615k
NIAID NIH HHS K01 AI083097NIAID NIH HHS K01AI083097
6 · The paper itself

Abstract

objectivesTo estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment.

methodsWe identified cohorts within Ovid Medline, ISI Web of Knowledge, Cochrane Database of Systematic Reviews and four conference abstract archives. We summarized retention rates from studies describing observational cohorts from sub-Saharan Africa reporting on adult HIV 1- infected patients initiating first-line three-drug ART. We estimated all-cause attrition rates for 6, 12, 18, 24, or 36 months after ART initiation including patients who died or were lost to follow-up (as defined by the author), but excluding transferred patients.

resultsWe analysed 33 sources describing 39 cohorts and 226 307 patients. Patients were more likely to be female (median 65%) and had a median age at initiation of 37 (range 34-40). Median starting CD4 count was 109 cells/mm(3). Loss to follow-up was the most common cause of attrition (59%), followed by death (41%). Median attrition at 12, 24 and 36 months was 22.6% (range 7%-45%), 25% (range 11%-32%) and 29.5% (range 13%-36.1%) respectively. After pooling data in a random-effects meta-analysis, retention declined from 86.1% at 6 months to 80.2% at 12 months, 76.8% at 24 months and 72.3% at 36 months. Adjusting for variable follow-up time in a sensitivity analysis, 24 month retention was 70.0% (range: 66.7%-73.3%), while 36 month retention was 64.6% (range: 57.5%-72.1%).

conclusionsOur findings document the difficulties in retaining patients in care for lifelong treatment, and the progress being made in raising overall retention rates.

Indexed as

Drug MonitoringAdultAfrica South of the SaharaAntiretroviral Therapy, Highly ActiveFemaleFollow-Up StudiesHIV InfectionsHumansMalePatient Dropouts

Identifiers

PMID20586956
PMCPMC2948795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.